Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

Published:2013-01 Issue:1 Volume:24 Page:90-96
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Besse B.,Tsao L.C.,Chao D.T.,Fang Y.,Soria J.-C.,Almokadem S.,Belani C.P.

Funder

Facet Biotech

Biogen Idec

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/1/90/13789315/mds281.pdf

Reference28 articles.

1. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial;Kelly;J Clin Oncol,2001

2. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer;Schiller;N Engl J Med,2002

3. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer;Scagliotti;J Clin Oncol,2008

4. Avastin (bevacizumab): prescribing information,2011

5. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Eng J Med,2006

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrins and NAFLD-associated liver diseases: clinical associations, pathophysiological mechanisms and pharmacological implications;Acta Biochimica et Biophysica Sinica;2024-09-01

2. A Ubiquitin‐Dependent Switch on MEF2D Senses Pro‐Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer;Advanced Science;2023-10-12

3. Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities;Cell Communication and Signaling;2023-09-28

4. Targeting integrin α5β1 in urological tumors: opportunities and challenges;Frontiers in Oncology;2023-07-06

5. Integrins in cancer: Emerging mechanisms and therapeutic opportunities;Pharmacology & Therapeutics;2023-07